Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

3 Things Rich Retirees Do Differently With Their Social Security Benefits

View original at nasdaq.com
3 Things Rich Retirees Do Differently With Their Social Security Benefits Key Points Many retirees need their Social Security to cover their basic expenses…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • AI could create the world's first trillionaire through a company providing critical technology that Nvidia and Intel both need

    60% confidence
  • 8% yearly return is a bit below the stock market's average

    60% confidence
  • Contributing $500 per month to a retirement account over 42 years with an 8% annual return could result in over $1.8 million in savings

    60% confidence
  • Wealthy retirees can delay their Social Security claims until age 70 without having to wait to retire because they have enough savings to live on

    60% confidence
  • A handful of little-known Social Security secrets could help ensure a boost in retirement income, with one trick potentially paying as much as $23,760 more each year

    60% confidence
  • Millions of older Americans today collect monthly benefits from Social Security

    60% confidence
  • You get an 8% boost to your monthly Social Security checks for each year you delay claiming beyond full retirement age, up until age 70

    60% confidence
  • For many retirees, Social Security benefits are a true lifeline, spelling the difference between covering essential bills or not

    60% confidence
  • Full retirement age is 67 for anyone born in 1960 or later

    60% confidence
  • Most Americans are a few years or more behind on retirement savings

    60% confidence
  • The earliest age to claim Social Security is 62

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
3 Things Rich Retirees Do Differently With Their Social Security Benefits — Source | Via News | Via News